Posts tagged KERX


Keryx Biopharmaceuticals (KERX): Boris Peaker Sees Big Hurdle Ahead for Auryxia’s Commercial Adoption

KERX pulled Auryxia guidance for the year after a rocky third quarter performance; Cowen’s Boris Peaker thumbs down.

Keryx Biopharmaceuticals (KERX): Focusing On Auryxia Growth

Maxim analyst Jason McCarthy is out today with a new research note on shares of Keryx Biopharmaceuticals …

Keryx Biopharmaceuticals (KERX) Reports 4Q and Full Year 2016 Results

Keryx Biopharmaceuticals (NASDAQ:KERX) announced its financial results for the fourth quarter and year ended December …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Publication of Auryxia Phase 3 Trial Results in JASN

Keryx Biopharmaceuticals (NASDAQ:KERX) announced the publication of results from its pivotal Phase 3 study evaluating …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week

Keryx Biopharmaceuticals (NASDAQ:KERX) announced case study data, which showed that Auryxia® (ferric citrate) lowered and …

Show More